cas 2940940-46-3|| where to buy 1-(4-bromo-2,6-difluoro-phenyl)-3-(2-trimethylsilylethoxymethyl)hexahydropyrimidine-2,4-dione

Nom du produit:1-(4-bromo-2,6-difluoro-phenyl)-3-(2-trimethylsilylethoxymethyl)hexahydropyrimidine-2,4-dione

IUPAC Name:1-(4-bromo-2,6-difluorophenyl)-3-{[2-(trimethylsilyl)ethoxy]methyl}-1,3-diazinane-2,4-dione

: CAS：2940940-46-3; Formule moléculaire：C16H21BrF2N2O3Si; Pureté：95%

Unité d'emballage	Stock disponible	Prix($)
CM1076165-100mg	in stock	ſſȌ
CM1076165-250mg	in stock	ɐɐɐ
CM1076165-500mg	in stock	ǆɐȷ
CM1076165-1g	in stock	ƋƋƋȷ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2940940-46-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2940940-46-3; Formule moléculaire:C16H21BrF2N2O3Si; Point de fusion:-; Code SMILES:C[Si](C)(C)CCOCN1C(=O)CCN(C1=O)C1=C(F)C=C(Br)C=C1F; Densité:

: Numéro de catalogue:CM1076165; Poids moléculaire:435.34; Point d'ébullition:; N° Mdl:; Stockage:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.